You are here
VBL Therapeutics to Present at Upcoming Conferences in October
TEL AVIV, Israel, Sept. 17, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the company will provide a corporate overview at two events during October, as detailed below. In addition the Company will present data on its novel MOSPD2 program at ECTRIMS 2018 - European Committee for Treatment and Research in Multiple Sclerosis.
|Cantor Fitzgerald Global Healthcare Conference - Presentation Details|
|Date:||Wednesday, October 3, 2018|
|Time:||10:20am Eastern Time|
|Location:||InterContinental New York Barclay Hotel, New York|
|Chardan Gene Therapy Conference - Presentation Details|
|Date:||Tuesday, October 9, 2018|
|Time:||1:30pm Eastern Time|
|Location:||Westin Grand Central Hotel, New York|
|ECTRIMS 2018 - Poster Presentation Details:|
|Abstract:||MOSPD2: A Novel Therapeutic Target for the Treatment of CNS Inflammation|
|Session title:||Poster Session 2|
|Date:||Thursday, October 11, 2018|
|Time:||5:15-7:15pm Central European Summer Time|
|Location:||City Cube Messe Berlin|
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.
Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding our product candidates, including VB-111, including their clinical development, therapeutic potential and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2017, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
LifeSci Advisors, LLC